TPD & Induced Proximity Summit Leaderboard
  • Sunday, June 21, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 47

Author

Pharma Journalist 8887 posts 0 comments

Alkermes to Acquire Avadel in $2.1 Billion Deal to Expand Into Sleep Medicine Market

Oct 24, 2025
Alkermes plc has announced plans to acquire Avadel Pharmaceuticals plc in a $2.1 billion all-cash deal, marking a major strategic move to expand its presence into the fast-growing sleep…
Read More...

Ipsen to Acquire ImCheck Therapeutics to Boost Immuno-Oncology Pipeline

Oct 24, 2025
Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

FDA Approves GSK’s Blenrep Combo for Relapsed or Refractory Multiple Myeloma

Oct 23, 2025
GSK plc announced today that the US Food and Drug Administration (FDA) has approved its cancer therapy Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and…
Read More...

Takeda and Innovent Partner in $1.2 Billion Deal to Advance Late-Stage Cancer Drugs Globally

Oct 23, 2025
Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Ventus Therapeutics Teams Up with Genentech for AI-Driven Drug Discovery Collaboration

Oct 22, 2025
Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced a multi-year collaboration with Genentech, part of the Roche Group, to discover and optimize novel…
Read More...

Roche’s Tecentriq Shows Survival Benefit in ctDNA-Guided Bladder Cancer Trial

Oct 22, 2025
Roche announced positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) in patients…
Read More...

EMA Backs Approval of GSK’s Shingrix in New Prefilled Syringe Format

Oct 21, 2025
GSK plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new prefilled…
Read More...

Just announced: AI in Drug Discovery 2026 agenda

Oct 21, 2025
SAE Media Group unveils the full agenda for AI in Drug Discovery Conference 400 ticket saving ends 7 November 2025. 2026, highlighting the technologies and strategies driving …
Read More...

FDA Approves Glaukos’ Epioxa, First Incision-Free Drug for Keratoconus

Oct 21, 2025
Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its novel corneal cross-linking therapy, Epioxa™ (Epioxa™ HD / Epioxa™), marking a major…
Read More...

Roche’s Tecentriq Extends Survival in Bladder Cancer Using ctDNA-Guided Approach

Oct 21, 2025
Roche has announced positive phase III results from its IMvigor011 study, showing that Tecentriq® (atezolizumab) significantly improves survival outcomes in patients with…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.